Overseas covid-19 testing reagent revenue increased Beijing Hotgen Biotech Co.Ltd(688068) net profit increased nearly 20 times in advance
As one of the covid-19 detection concept stocks, Beijing Hotgen Biotech Co.Ltd(688068) (688068) is expected to benefit from the increase of overseas covid-19 detection reagent revenue in 2021, and the company’s net profit will increase nearly 20 times year-on-year.
Through calculation, Beijing Hotgen Biotech Co.Ltd(688068) it is estimated that the net profit attributable to the owners of the parent company will reach 2 billion yuan to 2.35 billion yuan in 2021, an increase of 1.888 billion yuan to 2.238 billion yuan compared with the same period of last year, a year-on-year increase of 1684.65% to 1996.97%.
The company expects the net profit after deduction of non-profit to be RMB 1.987 billion to RMB 2.337 billion, with a year-on-year increase of 1696.17% to 2012.59%. Compared with 2020, Beijing Hotgen Biotech Co.Ltd(688068) achieved a net profit of 112 million yuan, a year-on-year increase of more than 3 times.
For the substantial growth of performance, the listed company said that in 2020, due to the covid-19 epidemic and the late certification of covid-19 antibody detection reagent in China, the operating performance was relatively small, resulting in a small base compared with 2021.
On the other hand, the order revenue of Beijing Hotgen Biotech Co.Ltd(688068) covid-19 antigen detection reagent from overseas increased in 2021.
In the first half of last year, the Beijing Hotgen Biotech Co.Ltd(688068) New Coronavirus antigen detection kit was earlier approved by the German Federal Drug and medical device Research Institute (BfArM) for home free testing, which resulted in the explosive growth of foreign trade orders in the first half of the year. In the second half of the year, the New Coronavirus antigen detection kit developed by the research and development company has obtained the self testing registration / filing of the EU CE and the major economies such as the British MHRA and French ANSM, and in the fourth quarter, the COVID-19 virus has been affected by the variation of delta virus and the Olympic game. When the demand for covid-19 antigen detection reagent increased significantly, the revenue of overseas covid-19 detection reagent increased significantly.
In terms of market performance, with the recurrence of covid-19 epidemic in the world, Beijing Hotgen Biotech Co.Ltd(688068) share price has risen rapidly since April 2021, and the monthly increase has rapidly exceeded 3 times; Subsequently, the stock price band fell in May, with a cumulative decline of about 40%.
In addition to covid-19 detection reagent, Beijing Hotgen Biotech Co.Ltd(688068) also lays out the field of early cancer screening.
Last December, Beijing Hotgen Biotech Co.Ltd(688068) obtained 38.1% equity of Aorui biology at the price of 153 million yuan through its own funds. It is not ruled out further capital increase and control in the future. Aorui biological is engaged in non-invasive early screening, early diagnosis and accurate diagnosis of cancer. With reference to its audited net assets of RMB 28.7304 million at the end of October 2021, the transaction premium rate is nearly 14 times.
In this regard, Beijing Hotgen Biotech Co.Ltd(688068) said that Aorui biological’s early screening field is strongly supported by national policies, has broad market prospects and is consistent with the company’s strategic development direction; In addition, Aorui biology has obvious advantages in technology and talents, and has obvious synergy with the company’s business. In the field of early screening and early diagnosis of liver cancer, Aorui biology has completed the development of two liver cancer diagnosis products, including a liver cancer auxiliary diagnosis product and a liver cancer screening product; The R & D of early screening products such as gastric cancer and lung cancer has been arranged in other single cancer fields; In the field of Pan cancer early screening, it has arranged the R & D of a variety of Pan cancer early screening products.
In addition, last September, Beijing Hotgen Biotech Co.Ltd(688068) invested 100 million yuan to establish Beijing Yaojing Gene Technology Co., Ltd. together with Lin Changqing, chairman of the company, and Beijing Yaojing enterprise management center, an employee stock ownership platform. After its establishment, Yaojing gene purchased the company’s “exosome related gene detection R & D project” according to the accumulated original book value of R & D projects.
It is reported that the transaction aims to expand gene detection technologies such as molecular detection, further optimize Beijing Hotgen Biotech Co.Ltd(688068) business structure, improve sustainable competitiveness and minimize the impact of R & D failure risk on main business; At the same time, share investment risks and realize corresponding incentives through the participation of actual controllers and key managers.
(Securities Times · e company)
